113173
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
工程仿生纳米胶束通过清除活性氧和重编程巨噬细胞靶向脓毒症相关急性肺损伤中的炎症
Authors Li Q, Sun H, Zhang X, Chen Y, Wu Z, Xia M, Sun L, Shi W, Sun Z, Li W, Ding L
Received 30 September 2025
Accepted for publication 17 December 2025
Published 26 December 2025 Volume 2025:20 Pages 15827—15845
DOI https://doi.org/10.2147/IJN.S565422
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Sachin Mali
Quan Li,1,* Haijun Sun,1,* Xinjing Zhang,2,* Yani Chen,1 Zhifeng Wu,1 Maohong Xia,1 Lu Sun,1 Weigang Shi,1 Zhaorui Sun,3 Wei Li,4 Lili Ding1
1Intensive Care Unit, Jiangsu Province (Suqian) Hospital, Suqian, Jiangsu, 223899, People’s Republic of China; 2Pulmonary and Critical Care Medicine, Jiangsu Province (Suqian) Hospital, Suqian, Jiangsu, 223899, People’s Republic of China; 3Department of Emergency Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, 210093, People’s Republic of China; 4Department of Emergency Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, 210029, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wei Li, Email liwei5477@jsph.org.cn Lili Ding, Email lzwlk20150221@163.com
Background: Sepsis-associated acute lung injury (SALI) has high mortality, largely driven by a damaging cycle of oxidative stress and inflammation, with a lack of effective treatments. To address this, a novel biomimetic nanodrug was developed. It uses an amphiphilic copolymer (PT) to encapsulate the antioxidant/anti-inflammatory agent carnosic acid (CA), forming PT@CA micelles. These micelles are then coated with M2 macrophage membranes (MM) to create MM@PT@CA. Compared to traditional liposomes, the macrophage membrane has better inflammatory targeting and biological safety.
Methods: The PT copolymer was synthesized by grafting thioctic acid onto polylysine. CA was encapsulated via anti-solvent precipitation to form PT@CA, which was subsequently coated with M2 macrophage membranes via co-extrusion to yield the final bionic nanomicelle, MM@PT@CA. The system’s ROS-responsive drug release, antioxidant, and antibacterial activities were characterized. Its biocompatibility, ability to scavenge cellular ROS, anti-inflammatory effects, and promotion of M2 macrophage polarization were assessed in vitro. Therapeutic efficacy was further evaluated in a mouse model of sepsis-induced lung injury.
Results: MM@PT@CA demonstrated significant multifunctional efficacy across a series of experiments. In vitro, it scavenged DPPH and ABTS radicals by 74.07% and 91.47%, respectively, and inhibited the growth of Staphylococcus aureus and Escherichia coli. It was efficiently taken up by cells and accumulated at inflammatory sites. Moreover, it exhibited excellent biocompatibility, remarkably restoring cell viability under oxidative stress from 48.70% to 93.85% while down-regulating pro-inflammatory factors. In vivo, MM@PT@CA treatment reduced apoptosis from 28.79% to 5.49%. Notably, the progression of SALI was effectively halted, which was attributed to its ability to modulate macrophage polarization and inhibit the pro-inflammatory cytokine storm.
Conclusion: The developed bionic nanomicelle targets inflammation, combats infection and oxidative stress, and ultimately alleviates SALI. These features highlight MM@PT@CA promising therapeutic potential for the treatment of SALI.
Keywords: acute lung injury, biomimetic nanomicelles, ROS scavenging, macrophage reprogramming, carnosic acid
1Intensive Care Unit, Jiangsu Province (Suqian) Hospital, Suqian, Jiangsu, 223899, People’s Republic of China; 2Pulmonary and Critical Care Medicine, Jiangsu Province (Suqian) Hospital, Suqian, Jiangsu, 223899, People’s Republic of China; 3Department of Emergency Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, 210093, People’s Republic of China; 4Department of Emergency Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, 210029, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wei Li, Email liwei5477@jsph.org.cn Lili Ding, Email lzwlk20150221@163.com
Background: Sepsis-associated acute lung injury (SALI) has high mortality, largely driven by a damaging cycle of oxidative stress and inflammation, with a lack of effective treatments. To address this, a novel biomimetic nanodrug was developed. It uses an amphiphilic copolymer (PT) to encapsulate the antioxidant/anti-inflammatory agent carnosic acid (CA), forming PT@CA micelles. These micelles are then coated with M2 macrophage membranes (MM) to create MM@PT@CA. Compared to traditional liposomes, the macrophage membrane has better inflammatory targeting and biological safety.
Methods: The PT copolymer was synthesized by grafting thioctic acid onto polylysine. CA was encapsulated via anti-solvent precipitation to form PT@CA, which was subsequently coated with M2 macrophage membranes via co-extrusion to yield the final bionic nanomicelle, MM@PT@CA. The system’s ROS-responsive drug release, antioxidant, and antibacterial activities were characterized. Its biocompatibility, ability to scavenge cellular ROS, anti-inflammatory effects, and promotion of M2 macrophage polarization were assessed in vitro. Therapeutic efficacy was further evaluated in a mouse model of sepsis-induced lung injury.
Results: MM@PT@CA demonstrated significant multifunctional efficacy across a series of experiments. In vitro, it scavenged DPPH and ABTS radicals by 74.07% and 91.47%, respectively, and inhibited the growth of Staphylococcus aureus and Escherichia coli. It was efficiently taken up by cells and accumulated at inflammatory sites. Moreover, it exhibited excellent biocompatibility, remarkably restoring cell viability under oxidative stress from 48.70% to 93.85% while down-regulating pro-inflammatory factors. In vivo, MM@PT@CA treatment reduced apoptosis from 28.79% to 5.49%. Notably, the progression of SALI was effectively halted, which was attributed to its ability to modulate macrophage polarization and inhibit the pro-inflammatory cytokine storm.
Conclusion: The developed bionic nanomicelle targets inflammation, combats infection and oxidative stress, and ultimately alleviates SALI. These features highlight MM@PT@CA promising therapeutic potential for the treatment of SALI.
Keywords: acute lung injury, biomimetic nanomicelles, ROS scavenging, macrophage reprogramming, carnosic acid